ClinicalTrials.gg
TerminatedNCT01389856FUTURE 4Updated Feb 4, 2025Results posted

Persistent Pulmonary Hypertension of the Newborn

A Phase 3 interventional study of Bosentan and Matching placebo in Persistent Pulmonary Hypertension of the Newborn, sponsored by Actelion. Terminated. Open to participants aged 12 Hours to 7 Days. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
To be compliant with the timelines as agreed with Paediatric Committee (PC) within the Paediatric Investigational Plan

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
12 Hours to 7 Days
Sex
All
01

Study summary

The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a supporting and safe therapy and to evaluate the pharmacokinetics of bosentan and its metabolites.

02

Conditions studied

  • Persistent Pulmonary Hypertension of the Newborn

Keywords

  • Persistent pulmonary hypertension, newborn
  • PPHN
03

In context

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

This study's enrollment of 23 is below the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.

Browse Persistent Fetal Circulation Syndrome studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Hours to 7 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed by the parent(s) or the legal representative(s).
  2. Term and near term newborns (gestational age > 34 weeks).
  3. Post natal age ≥ 12 hours and \< 7 days.
  4. Weight at birth ≥ 2,000 g.
  5. Idiopathic PPHN or PPHN due to parenchymal lung disease
  6. Documented diagnosis of pulmonary hypertension (PH) confirmed by echocardiography.
  7. Need for continued inhaled nitric oxide (iNO) at a dose > 10ppm after at least 4 hours of continuous iNO treatment.
  8. Two oxygenation index (OI) values ≥ 12 taken at least 30 minutes apart, in the 12 hours prior to randomization and while the patient is receiving iNO treatment.
  9. Mechanical ventilation with fraction of inspired oxygen (FiO2) ≥ 50% at randomization.

Exclusion criteria

Exclusion Criteria:

  1. PH associated with conditions other than PPHN.
  2. Immediate need for cardiac resuscitation or extracorporeal membrane oxygenation (ECMO).
  3. Lethal congenital anomalies.
  4. Congenital Diaphragmatic Hernia.
  5. Significant structural cardiac anomalies.
  6. Medically significant pneumothorax.
  7. Active seizures.
  8. Expected duration of mechanical ventilation of less than 48 hours.
  9. Mean systemic blood pressure \< 35 mmHg despite therapy with volume infusions and cardiotonic support.
  10. Hepatic failure or all conditions with (ALT) values > 2 x (ULN).
  11. Renal function impairment such as serum creatinine > 3 x ULN or anuria.
  12. Known intracranial hemorrhage grade III or IV.
  13. Either or hematocrit level \< 75% of the lower limit of normal (LLN).
  14. Thrombocytopenia ( count \< 50,000 cells /µL).
  15. Leukopenia (WBC \< 2,500 cells/ µL).
  16. Any condition precluding the use of a nasogastric/orogastric tube.
  17. Administration of prohibited medication prior to randomization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    1

    Bosentan

    Drug: Bosentan

  • Placebo comparator
    2

    Matching placebo

    Drug: Matching placebo

Interventions

  • 2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.

    Also known as: Tracleer

  • DrugMatching placebo

    twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Treatment Failure

    Treatment failure was defined as the need for extra corporeal membrane oxygenation or initiation of alternative pulmonary vasodilator treatment

    Time frame: From baseline to up to 21 days

  2. Time to Complete Weaning From iNO

    Calculated from the time from first study drug administration to complete weaning from iNO. Weaning from iNO was considered complete if there was no requirement for the re-initiation of iNO within 24 h after stopping

    Time frame: From baseline to up to 21 days

  3. Time to Complete Weaning From Mechanical Ventilation

    Calculated from the time from first study drug administration to complete weaning from mechanical ventilation

    Time frame: From baseline to up to 21 days

Secondary outcomes

  1. Percentage of Patients Requiring Re-initiation of iNO Therapy

    Re-initiation of iNO therapy following weaning from iNO therapy

    Time frame: From baseline to up to 21 days

  2. Percentage of Patients With Pulmonary Hypertension (PH) at End of Treatment

    The presence of PH was assessed by echocardiography. PH was reported as 'present' if at least one of the following criteria was met: * Shunt through ductus arteriosus was either 'predominant right to left' or 'bidirectional' * Shunt through foramen ovale was either 'predominant right to left' or 'bidirectional' * Marked right ventricular dilation was ticked 'present' * Paradoxical shift of intraventricular septum was ticked 'present' * Right ventricular systolic pressure (mmHg) was \> 2/3 of the reported systemic blood pressure

    Time frame: From baseline to up to 14 days

  3. Change in Oxygenation Index (OI) From Baseline to 3 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 3 hours

  4. Change in Oxygenation Index (OI) From Baseline to 5 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 5 hours

  5. Change in Oxygenation Index (OI) From Baseline to 12 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 12 hours

  6. Change in Oxygenation Index (OI) From Baseline to 24 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 24 hours

  7. Change in Oxygenation Index (OI) From Baseline to 48 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 48 hours

  8. Change in Oxygenation Index (OI) From Baseline to 72 Hours Following Study Drug Administration

    The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

    Time frame: 72 hours

  9. Change in Arterial Blood Gas (ABG) pH From Baseline to 72 Hours Following Study Drug Administration

    pH was determined in arterial blood samples at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  10. Change in Arterial Blood Oxygen Saturation (SaO2) From Baseline to 72 Hours Following Study Drug Administration

    SaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  11. Change in Partial Pressure of Oxygen (PaO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration

    PaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  12. Change in Partial Pressure of Carbon Dioxide (PaCO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration

    PaCO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  13. Change in Pre-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration

    Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  14. Change in Post-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration

    Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  15. Change in Fraction of Inspired Oxygen (FiO2) From Baseline to 72 Hours Following Study Drug Administration

    FiO2 was determined according to each study centers' standard procedure at baseline and 72 h after the first study drug administration

    Time frame: 72 hours

  16. Maximum Whole Blood Concentration (Cmax) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Cmax was obtained directly from the measured concentrations. Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.

    Time frame: up to 12 hours

  17. Cmax for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 5

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Cmax obtained directly from the measured concentrations . Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.

    Time frame: 12 hours

  18. Time to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

    Time frame: up to 12 hours

  19. Tmax for Ro 47-8634 on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

    Time frame: up to 12 hours

  20. Tmax for Ro 48-5033 on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

    Time frame: up to 12 hours

  21. Tmax for Ro 64-1056 on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

    Time frame: up to 12 hours

  22. Tmax for Bosentan on Day 5

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

    Time frame: 12 hours

  23. Tmax for Ro 47-8634 on Day 5

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

    Time frame: 12 hours

  24. Tmax for Ro 48-5033 on Day 5

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

    Time frame: 12 hours

  25. Tmax for Ro 64-1056 on Day 5

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

    Time frame: 12 hours

  26. Area Under the Concentration-time Curve Over a Period of 12 h (AUC0-12 Day 1)) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-12 Day 1 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.

    Time frame: 12 hours

  27. Area Under the Concentration-time Curve Over a Dosing Interval at Steady State on Day 5 (AUCtau) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUCtau Day 5 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.

    Time frame: 5 days

  28. Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 1 (AUC0-24C Day 1) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 1 was calculated as a multiple of AUC0-12, (2 × AUC0-12 for 2 times daily dosing) corrected to 2 mg/kg.

    Time frame: 24 hours

  29. Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 5 (AUC0-24C Day 5) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 5 was calculated as a multiple of AUCtau, (2 × AUCtau for 2 times daily dosing) corrected to 2 mg/kg.

    Time frame: 24 hours

  30. Accumulation Index (AI) for Bosentan

    Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Days 1 and 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AI was calculated as the ratio AUCtau /AUC0-12 for the subjects having PK samples collected on Day 1 and Day 5 and with AUC0-12 \> 0 ng.h/mL.

    Time frame: 5 days

07

Results

Posted Mar 23, 2015

Participant flow

First patient, first visit was 8 December 2011 and last patient, last visit was 5 December 2013. The investigational sites were tertiary care centers with neonatal intensive care unit facilities at which inhaled nitric oxide (iNO) was used as standard of care for persistent pulmonary hypertension of the newborn (PPHN).

Participant flow — Overall Study
MilestoneBosentanPlacebo
Started138
Completed138
Not completed00

Outcome measures

PrimaryPercentage of Patients With Treatment Failure

Treatment failure was defined as the need for extra corporeal membrane oxygenation or initiation of alternative pulmonary vasodilator treatment

Time frame:
From baseline to up to 21 days
Reported as:
Number · percentage of participants
Percentage of Patients With Treatment Failure
percentage of participantsBosentanPlacebo
Percentage of Patients With Treatment Failure7.70
Statistical analysis
  • Bosentan vs Placebo · Fisher Exact · p = 1
PrimaryTime to Complete Weaning From iNO

Calculated from the time from first study drug administration to complete weaning from iNO. Weaning from iNO was considered complete if there was no requirement for the re-initiation of iNO within 24 h after stopping

Time frame:
From baseline to up to 21 days
Reported as:
Median · days
Time to Complete Weaning From iNO
daysBosentanPlacebo
Time to Complete Weaning From iNO3.7 (1.17 to 6.95)2.9 (1.26 to 4.23)
Statistical analysis
  • Bosentan vs Placebo · Log Rank · p = 0.3407
PrimaryTime to Complete Weaning From Mechanical Ventilation

Calculated from the time from first study drug administration to complete weaning from mechanical ventilation

Time frame:
From baseline to up to 21 days
Reported as:
Median · days
Time to Complete Weaning From Mechanical Ventilation
daysBosentanPlacebo
Time to Complete Weaning From Mechanical Ventilation10.8 (3.21 to 12.21)8.6 (3.71 to 9.66)
Statistical analysis
  • Bosentan vs Placebo · Log Rank · p = 0.2399
SecondaryPercentage of Patients Requiring Re-initiation of iNO Therapy

Re-initiation of iNO therapy following weaning from iNO therapy

Time frame:
From baseline to up to 21 days
Reported as:
Number · percentage of participants
Percentage of Patients Requiring Re-initiation of iNO Therapy
percentage of participantsBosentanPlacebo
Percentage of Patients Requiring Re-initiation of iNO Therapy00
SecondaryPercentage of Patients With Pulmonary Hypertension (PH) at End of Treatment

The presence of PH was assessed by echocardiography. PH was reported as 'present' if at least one of the following criteria was met: * Shunt through ductus arteriosus was either 'predominant right to left' or 'bidirectional' * Shunt through foramen ovale was either 'predominant right to left' or 'bidirectional' * Marked right ventricular dilation was ticked 'present' * Paradoxical shift of intraventricular septum was ticked 'present' * Right ventricular systolic pressure (mmHg) was \> 2/3 of the reported systemic blood pressure

Time frame:
From baseline to up to 14 days
Reported as:
Number · percentage of participants
Percentage of Patients With Pulmonary Hypertension (PH) at End of Treatment
percentage of participantsBosentanPlacebo
Percentage of Patients With Pulmonary Hypertension (PH) at End of Treatment41.737.5
Statistical analysis
  • Bosentan vs Placebo · Fisher Exact · p = 1.000
SecondaryChange in Oxygenation Index (OI) From Baseline to 3 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
3 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 3 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline18.3 (8.2 to 35.4)13.2 (7.9 to 39.4)
3 hours17.3 (6.9 to 33.3)13.0 (8.5 to 42.9)
Change from baseline-1.6 (-5.1 to 3.3)1.1 (-6.1 to 6.1)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.2235
SecondaryChange in Oxygenation Index (OI) From Baseline to 5 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
5 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 5 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline18.3 (8.2 to 35.4)13.2 (7.9 to 39.4)
5 hours16.7 (7.9 to 36.7)13.3 (6.7 to 28.6)
Change from baseline-0.9 (-4.7 to 4.5)-5.6 (-7.5 to 15.7)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.1468
SecondaryChange in Oxygenation Index (OI) From Baseline to 12 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
12 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 12 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline18.3 (8.2 to 35.4)13.2 (7.9 to 39.4)
12 hours14.3 (8.3 to 26.7)11.1 (4.9 to 19.6)
Change from baseline-0.8 (-12.9 to 2.8)-3.9 (-14.6 to 12.5)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.0789
SecondaryChange in Oxygenation Index (OI) From Baseline to 24 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
24 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 24 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline18.3 (8.2 to 35.4)13.2 (7.9 to 39.4)
24 hours13.1 (6.5 to 32.9)11.8 (5.2 to 26.4)
Change from baseline-4.9 (-17.0 to 1.1)-6.9 (-9.9 to 19.4)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.3723
SecondaryChange in Oxygenation Index (OI) From Baseline to 48 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
48 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 48 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline19.4 (8.2 to 35.4)13.2 (7.9 to 39.4)
48 hours11.5 (4.7 to 21.0)3.8 (2.5 to 10.8)
Change from baseline-4.9 (-15.5 to -2.1)-9.9 (-18.0 to 3.4)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.0569
SecondaryChange in Oxygenation Index (OI) From Baseline to 72 Hours Following Study Drug Administration

The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.

Time frame:
72 hours
Reported as:
Median · oxygenation index
Change in Oxygenation Index (OI) From Baseline to 72 Hours Following Study Drug Administration
oxygenation indexBosentanPlacebo
Baseline19.4 (8.2 to 35.4)13.2 (7.9 to 39.4)
72 hours6.7 (4.2 to 17.0)3.9 (3.7 to 10.8)
Change from baseline-8.9 (-23.1 to -1.8)-9.4 (-17.7 to 2.2)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.1015
SecondaryChange in Arterial Blood Gas (ABG) pH From Baseline to 72 Hours Following Study Drug Administration

pH was determined in arterial blood samples at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · pH
Change in Arterial Blood Gas (ABG) pH From Baseline to 72 Hours Following Study Drug Administration
pHBosentanPlacebo
Baseline7.37 (7.30 to 7.43)7.31 (7.21 to 7.49)
72 hours7.37 (7.36 to 7.43)7.36 (7.30 to 7.39)
Change from baseline0.04 (-0.06 to 0.07)0.02 (-0.09 to 0.19)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.0824
SecondaryChange in Arterial Blood Oxygen Saturation (SaO2) From Baseline to 72 Hours Following Study Drug Administration

SaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · percentage saturation
Change in Arterial Blood Oxygen Saturation (SaO2) From Baseline to 72 Hours Following Study Drug Administration
percentage saturationBosentanPlacebo
Baseline95.0 (92.0 to 99.0)95.5 (89.0 to 99.0)
72 hours98.0 (95.0 to 100.0)97.0 (93.0 to 100.0)
Change from baseline1.0 (0.0 to 8.0)0.0 (-4.0 to 21.0)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.3863
SecondaryChange in Partial Pressure of Oxygen (PaO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration

PaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · mm Hg
Change in Partial Pressure of Oxygen (PaO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration
mm HgBosentanPlacebo
Baseline61.0 (53.0 to 132.0)69.5 (46.0 to 111.0)
72 hours81.0 (61.0 to 104.0)81.5 (56.0 to 187.0)
Change from baseline18.0 (-13.0 to 32.0)6.0 (-12.0 to 115.0)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.3936
SecondaryChange in Partial Pressure of Carbon Dioxide (PaCO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration

PaCO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · mm Hg
Change in Partial Pressure of Carbon Dioxide (PaCO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration
mm HgBosentanPlacebo
Baseline40.5 (31.0 to 47.0)46.0 (35.0 to 57.0)
72 hours45.5 (36.0 to 49.0)46.0 (41.0 to 64.0)
Change from baseline6.0 (-1.0 to 12.0)8.0 (-8.0 to 21.0)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.2436
SecondaryChange in Pre-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration

Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · percentage saturation
Change in Pre-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration
percentage saturationBosentanPlacebo
Baseline95.00 (91.00 to 99.00)97.00 (91.00 to 99.00)
72 hours96.00 (93.00 to 100.00)96.00 (85.00 to 100.00)
Change from baseline0.50 (-2.00 to 2.00)-1.00 (-10.00 to 2.00)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.1756
SecondaryChange in Post-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration

Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · percentage saturation
Change in Post-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration
percentage saturationBosentanPlacebo
Baseline96.5 (92.0 to 99.0)96.0 (89.0 to 98.0)
72 hours95.5 (94.0 to 99.0)97.5 (95.0 to 100.0)
Change from baseline0.0 (-2.0 to 3.0)2.0 (1.0 to 12.0)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.1155
SecondaryChange in Fraction of Inspired Oxygen (FiO2) From Baseline to 72 Hours Following Study Drug Administration

FiO2 was determined according to each study centers' standard procedure at baseline and 72 h after the first study drug administration

Time frame:
72 hours
Reported as:
Median · percentage of oxygen
Change in Fraction of Inspired Oxygen (FiO2) From Baseline to 72 Hours Following Study Drug Administration
percentage of oxygenBosentanPlacebo
Baseline90.0 (62.0 to 97.0)78.0 (60.0 to 100.0)
72 hours51.5 (28.0 to 60.0)40.0 (25.0 to 60.0)
Change from baseline-33.5 (-50.0 to -15.0)-35.5 (-60.0 to 0.0)
Statistical analysis
  • Bosentan vs Placebo · Non-parametric ANCOVA · p = 0.1400
SecondaryMaximum Whole Blood Concentration (Cmax) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Cmax was obtained directly from the measured concentrations. Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.

Time frame:
up to 12 hours
Reported as:
Geometric mean · ng/mL
Maximum Whole Blood Concentration (Cmax) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1
ng/mLBosentan
Bosentan30.1 (2.4 to 372.2)
Ro 47-86340.1 (0.0 to 1.1)
Ro 48-50330.6 (0.0 to 18.3)
Ro 64-10560.9 (0.0 to 16.2)
SecondaryCmax for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 5

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Cmax obtained directly from the measured concentrations . Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.

Time frame:
12 hours
Reported as:
Geometric mean · ng/mL
Cmax for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 5
ng/mLBosentan
Bosentan880.0 (339.2 to 2282.7)
Ro 47-863424.9 (9.0 to 69.1)
Ro 48-5033292.3 (115.8 to 738.1)
Ro 64-1056136.0 (77.4 to 238.8)
SecondaryTime to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

Time frame:
up to 12 hours
Reported as:
Median · hours
Time to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 1
hoursBosentan
Time to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 112.0 (7.5 to 12.0)
SecondaryTmax for Ro 47-8634 on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

Time frame:
up to 12 hours
Reported as:
Median · hours
Tmax for Ro 47-8634 on Day 1
hoursBosentan
Tmax for Ro 47-8634 on Day 112.0 (7.5 to 12.0)
SecondaryTmax for Ro 48-5033 on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

Time frame:
up to 12 hours
Reported as:
Median · hours
Tmax for Ro 48-5033 on Day 1
hoursBosentan
Tmax for Ro 48-5033 on Day 112.0 (12.0 to 12.0)
SecondaryTmax for Ro 64-1056 on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.

Time frame:
up to 12 hours
Reported as:
Median · hours
Tmax for Ro 64-1056 on Day 1
hoursBosentan
Tmax for Ro 64-1056 on Day 112 (0.5 to 12.0)
SecondaryTmax for Bosentan on Day 5

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

Time frame:
12 hours
Reported as:
Median · hours
Tmax for Bosentan on Day 5
hoursBosentan
Tmax for Bosentan on Day 57.5 (0.8 to 12.0)
SecondaryTmax for Ro 47-8634 on Day 5

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

Time frame:
12 hours
Reported as:
Median · hours
Tmax for Ro 47-8634 on Day 5
hoursBosentan
Tmax for Ro 47-8634 on Day 56.5 (0.8 to 12.0)
SecondaryTmax for Ro 48-5033 on Day 5

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

Time frame:
12 hours
Reported as:
Median · hours
Tmax for Ro 48-5033 on Day 5
hoursBosentan
Tmax for Ro 48-5033 on Day 57.5 (0.8 to 12.0)
SecondaryTmax for Ro 64-1056 on Day 5

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.

Time frame:
12 hours
Reported as:
Median · hours
Tmax for Ro 64-1056 on Day 5
hoursBosentan
Tmax for Ro 64-1056 on Day 512.0 (7.5 to 12.0)
SecondaryArea Under the Concentration-time Curve Over a Period of 12 h (AUC0-12 Day 1)) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-12 Day 1 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.

Time frame:
12 hours
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve Over a Period of 12 h (AUC0-12 Day 1)) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1
h*ng/mLBosentan
Bosentan163.9 (9.6 to 2795.4)
Ro 47-86340.1 (0.0 to 3.7)
Ro 48-50331.4 (0.0 to 69.9)
Ro 64-10562.2 (0.1 to 64.1)
SecondaryArea Under the Concentration-time Curve Over a Dosing Interval at Steady State on Day 5 (AUCtau) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUCtau Day 5 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.

Time frame:
5 days
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve Over a Dosing Interval at Steady State on Day 5 (AUCtau) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
h*ng/mLBosentan
Bosentan6165.4 (2429.6 to 15645.3)
Ro 47-8634217.3 (75.3 to 626.8)
Ro 48-50332839.5 (1155.2 to 6979.2)
Ro 64-10561321.7 (729.5 to 2395.0)
SecondaryArea Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 1 (AUC0-24C Day 1) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 1 was calculated as a multiple of AUC0-12, (2 × AUC0-12 for 2 times daily dosing) corrected to 2 mg/kg.

Time frame:
24 hours
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 1 (AUC0-24C Day 1) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
h*ng/mLBosentan
Bosentan287.5 (15.0 to 5504.7)
Ro 47-86340.1 (0.0 to 6.1)
Ro 48-50332.0 (0.0 to 125.8)
Ro 64-10563.4 (0.1 to 120.8)
SecondaryArea Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 5 (AUC0-24C Day 5) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 5 was calculated as a multiple of AUCtau, (2 × AUCtau for 2 times daily dosing) corrected to 2 mg/kg.

Time frame:
24 hours
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 5 (AUC0-24C Day 5) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
h*ng/mLBosentan
Bosentan11530.2 (4507.0 to 29497.5)
Ro 47-8634406.3 (139.8 to 1180.9)
Ro 48-50335310.3 (2184.4 to 12908.9)
Ro 64-10562471.9 (1386.1 to 4408.0)
SecondaryAccumulation Index (AI) for Bosentan

Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Days 1 and 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AI was calculated as the ratio AUCtau /AUC0-12 for the subjects having PK samples collected on Day 1 and Day 5 and with AUC0-12 \> 0 ng.h/mL.

Time frame:
5 days
Reported as:
Geometric mean · accumulation index
Accumulation Index (AI) for Bosentan
accumulation indexBosentan
Accumulation Index (AI) for Bosentan61.6 (0.5 to 7813.9)

Adverse events

Collected over Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan—2/13 (15.4%)9/13 (69.2%)
Placebo—3/8 (37.5%)2/8 (25%)
Most frequent serious events
Most frequent serious events
EventBosentanPlacebo
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders0/132/8
SEPSISInfections and infestations0/131/8
HEPATITISHepatobiliary disorders1/130/8
METABOLIC ACIDOSISMetabolism and nutrition disorders1/130/8
HYPERCAPNIARespiratory, thoracic and mediastinal disorders1/130/8
CIRCULATORY COLLAPSEVascular disorders1/130/8
Most frequent other events
Showing 10 of 21
Most frequent other events
EventBosentanPlacebo
ANAEMIABlood and lymphatic system disorders3/131/8
GENERALISED OEDEMAGeneral disorders3/130/8
VOMITINGGastrointestinal disorders2/130/8
COAGULOPATHYBlood and lymphatic system disorders1/131/8
HYPOGLYCAEMIAMetabolism and nutrition disorders0/131/8
HYPOKALAEMIAMetabolism and nutrition disorders0/131/8
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders0/131/8
METABOLIC ACIDOSISMetabolism and nutrition disorders0/131/8
BILIRUBIN CONJUGATED INCREASEDInvestigations1/130/8
BODY TEMPERATURE INCREASEDInvestigations1/130/8

Baseline characteristics

Randomized and treated patients

Age, Continuous
Age, Continuous(days)BosentanPlaceboTotal
Median1.4 (0.6 to 5.6)1.7 (0.6 to 5.9)1.4 (0.6 to 5.9)
Sex: Female, Male
Sex: Female, Male(Participants)BosentanPlaceboTotal
Female9615
Male426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BosentanPlaceboTotal
Caucasian/white11617
Asian101
Hispanic112
Other011
Region of Enrollment
Region of Enrollment(participants)BosentanPlaceboTotal
Czech Republic112
France101
Korea, Republic of101
Poland538
United Kingdom426
United States123
Gestational age
Gestational age(weeks)BosentanPlaceboTotal
Median40.0 (36.0 to 41.0)38.5 (36.0 to 42.0)39.0 (36.0 to 42.0)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Steinhorn RH, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P, Pierce CM, Beghetti M; FUTURE-4 study investigators. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr. 2016 Oct;177:90-96.e3. doi: 10.1016/j.jpeds.2016.06.078. Epub 2016 Aug 5. PubMed 27502103 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2011
First posted
Jul 8, 2011
Start
Dec 2011
Primary completionActual
Dec 2013
CompletionActual
Jan 2014
Results first posted
Mar 23, 2015
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01389856
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jul 8, 2011
Start date
Dec 2011
Primary completion
Dec 2013
Completion
Jan 2014
Results posted
Mar 23, 2015
Last update
Feb 4, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion